Biscayne Neurotherapeutics, Inc.

Biscayne Neurotherapeutics, Inc. specializes in developing innovative neurotherapeutic solutions aimed at improving patient outcomes in neurological disorders. The company focuses on bringing advanced treatments to market through strategic collaborations and research initiatives. Biscayne Neurotherapeutics, Inc.

is involved in the development and commercialization of neurotherapeutic products. In September 2018, Supernus Pharmaceuticals, Inc. agreed to acquire Biscayne Neurotherapeutics, Inc. for up to USD 185 million, which includes a USD 15 million upfront payment, with additional milestones based on development and sales performance.

The company operates out of Miami, US, and was founded with a vision of enhancing treatment options for patients with neurological conditions. The transaction is expected to close shortly after the agreement date. BiscayNeNeuRo. com is primarily focused on the domain name industry, offering high-value domain names for purchase.

The core product offering consists of premium domain names, including BiscayNeNeuRo. com itself, which is marketed at a price of USD 5,495 with an option for a payment plan. The company serves a diverse clientele, ranging from individual entrepreneurs to established businesses seeking to enhance their online presence through unique and memorable web addresses. These domain names are utilized for a variety of purposes, including e-commerce sites, personal branding, and professional services, facilitating easier access for consumers and improving brand visibility.

The geographical markets for these offerings are global, as domain acquisition and online presence are pivotal for businesses and individuals worldwide, transcending local boundaries. BiscayNeNeuRo. com generates revenue through the sale of its premium domain names, structured to accommodate various purchasing preferences, including outright purchases and installment payment plans. Clients can opt for a straightforward one-time payment or choose to pay USD 457.

92 per month over a 12-month period, providing flexibility for buyers. This model appeals to a wide array of customers looking to establish a web presence without the burden of upfront costs. Revenue is derived directly from the sale of these domains, as customers complete transactions through secure payment methods, such as PayPal or Escrow. com.

The company emphasizes customer satisfaction with a 30-day money-back guarantee, reinforcing its commitment to providing a reliable and secure shopping experience for its clients. In September 2018, Supernus Pharmaceuticals, Inc. has agreed to acquire Biscayne Neurotherapeutics, Inc. for up to USD 185 million.

The initial payment of USD 15 million will be complemented by USD 75 million in development milestones and up to USD 95 million based on sales performance. The acquisition is expected to close shortly, positioning Biscayne Neurotherapeutics for growth in the neurotherapeutic market.